Richard A. Friesner, Ph.D. - Co-founder, Board Member, and Scientific Advisory Chairman
Paul Anderson, Ph.D. - Merck, retired
Bruce J. Berne, Ph.D. - Columbia University
John Chodera, Ph.D. - Sloan-Kettering Institute and MSKCC
William A. Goddard, III, Ph.D. - California Institute of Technology
Wayne C. Guida, Ph.D. - University of South Florida
Barry Honig, Ph.D. - Columbia University
Matthew P. Jacobson, Ph.D. - University of California, San Francisco
William L. Jorgensen, Ph.D. - Yale University
Ronald M. Levy, Ph.D. - Rutgers University
Mark Murcko, Ph.D. - Relay Therapeutics
Vijay Pande, Ph.D. - Stanford University
Richard A. Friesner is Professor of Chemistry at Columbia University and Director of the Columbia Center for Biomolecular Simulation. He is a member of the National Academy of Sciences and American Academy of Arts of Sciences, and has been awarded a Sloan Foundation Fellowship, Camille and Henry Dreyfus Teacher-Scholar Award, and an NIH Research Career Development Award. Current interests include quantum chemistry, development of potential functions for molecular simulation, continuum electrostatic models, and protein folding. Dr. Friesner is a co-founder of Schrödinger, and a member of Schrödinger's Board of Directors.
Dr. Paul Anderson currently serves on the Board of Directors of several companies and the Chemical Heritage Foundation. In 2009, he is Chairman of the Board of Trustees of the Gordon Research Conferences. During his celebrated career at Merck, Dr. Anderson and coworkers developed TRUSOPT, the first topical carbonic anhydrase inhibitor for treating glaucoma, and ZOCOR, a frequently prescribed drug for lowering cholesterol levels. Dr. Anderson has directed extensive medicinal chemistry efforts at Merck and DuPont Pharmaceuticals Company focused on new chemotherapy for AIDS, resulting in CRIXIVAN and SUSTIVA. Dr. Anderson is the recipient of countless awards, including in 2006 the American Chemical Society recognized Dr. Anderson with its highest honor, the Priestley Medal. In addition, Dr. Anderson has served as Chairman of the Medicinal Chemistry Division of the American Chemical Society, Chairman of the Gordon Research Conference on Medicinal Chemistry, Chairman of the NIH Study Section on Bioorganic Chemistry and Natural Products, as well as being a member of the National Advisory General Medicinal Sciences Council of the National Institutes of Health and the National Research Council, Board on Chemical Sciences and Technology.
Bruce J. Berne is Higgins Professor of Chemistry at Columbia University. He carried out the first molecular dynamics simulation for particles larger than an atom in the late 1960's. He has been awarded the ACS Award in Theoretical Chemistry and was elected a Fellow of the Academy of Arts and Sciences. In 1998, he was elected to the National Academy of Sciences. Current research areas include chemical dynamics, liquid state theory, developing new methods for molecular simulations, and construction of polarizable force fields.
John D. Chodera is an Assistant Member at the Sloan-Kettering Institute and Memorial Sloan-Kettering Cancer Center, and an Assistant Professor in the Physiology, Biophysics, and Systems Biology Program at the Weill Cornell Graduate School of Medical Sciences. He has spent over a decade developing efficient algorithms for conducting and analyzing molecular simulations to characterize biomolecular thermodynamics and kinetics. His laboratory at MSKCC uses both computation and experiment to advance the utility of alchemical free energy methods for the rational design of potent, selective small-molecule therapeutics.
Wayne C. Guida is Professor in the Department of Chemistry, University of South Florida in Tampa and Professor in the Drug Discovery Program at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida. He previously served as President and CEO of Schrödinger, Inc. and continues to serve on the company’s Board of Directors. Prior to his role as CEO of Schrödinger, he was Executive Director of Biomolecular Structure, Lead Finding, and Computing at the Novartis Institute for Biomedical Research (formerly CIBA-Geigy Pharmaceuticals), where he supervised a group of scientists engaged in molecular modeling, structural bioinformatics, X-ray crystallography, protein NMR spectroscopy, protein biochemistry, and high-throughput screening. His work at CIBA-Geigy, along with collaborators at several other institutions, resulted in one of the first successful examples of the use of structure-based drug design in drug discovery. That work led to the development of clinically tested inhibitors of purine nucleoside phosphorylase. Prior to joining CIBA-Geigy, Dr. Guida was one of the original developers of the MacroModel program at Columbia University.
Barry Honig is a biophysicist who specializes in bioinformatics and in developing theoretical methods for analyzing the physical chemical properties of macromolecules. He is particularly noted for innovating methods to compute and display the electrostatic potentials of macromolecules based on their 3D structures. The computer programs DelPhi and GRASP were developed in his laboratory and are widely used by the academic and industrial communities.
Since 1981, Dr. Honig has been a Professor of Biochemistry and Molecular Biophysics at Columbia University. In 1990, Dr. Honig was elected President of the Biophysical Society, he received an NIH Merit Award in 1995, and he is a recipient of the 2002 Founders Award of the Biophysical Society. Dr. Honig is a Howard Hughes Medical Institute (HHMI) Investigator. He serves on the editorial boards of several journals and has published over 190 scientific papers throughout his distinguished career.
Matthew P. Jacobson is an Associate Professor and Vice Chair in the Department of Pharmaceutical Chemistry at UCSF. He is the recipient of an NSF Career award and an Alfred P. Sloan Fellowship. Research interests in the area of computer-aided drug design include docking against homology models and flexible protein binding sites, membrane permeability, and antibody modeling. Other research interests include mechanisms of protein regulation by post-translational modifications, allostery, and pH.
William L. Jorgensen is the C. P. Whitehead Professor of Chemistry at Yale University. Jorgensen is the developer of the Optimized Potentials for Liquid State (OPLS) potential functions for organic molecules (including proteins). He pioneered the methodology of developing potential functions by fitting parameters to reproduce the thermodynamic properties of pure liquids, which is now widely used by other workers. He authored the QikProp program for ADME property prediction. Other interests include calculation of the rates of chemical reactions of organic molecules in liquids, determination of protein-ligand binding energies via free energy perturbation theory, and methods for Monte Carlo simulations.
Ronald M. Levy is Professor of Chemistry at Rutgers University. His research is primarily in the areas of protein simulation and modeling and molecular solvation. He has been awarded a Sloan Foundation Fellowship, a Johnson and Johnson Discovery Research Award, an NIH Research Career Development Award, and a Guggenheim Fellowship. Over the past decade he has developed the IMPACT molecular modeling code. Current interests include calculation of pKa's in proteins, development of polarizable potentials, new molecular simulation methods, and determination of solvation free energies.
Mark Murcko is the Chief Scientific Officer of Relay Therapeutics, and has been an advisor and consultant for Schrödinger since 2008. Prior to that, he was Vice President, Chief Technology Officer and Chair of the Scientific Advisory Board of Vertex Pharmaceuticals. Dr. Murcko is a co-inventor of Incivek™ (telaprevir), the world's most widely prescribed HCV protease inhibitor, as well as Agenerase™ (amprenavir) and Lexiva™ (fosamprenavir), Vertex's two marketed drugs for HIV. He is also a co-inventor of 8 other clinical candidates in the areas of cancer, inflammation/immunology, and infectious disease and was responsible for starting many of Vertex's programs in these and other disease areas. Prior to Vertex, Dr. Murcko worked at Merck Sharpe & Dohme, where he helped discover clinical candidates against cardiovascular and ocular diseases, including inhibitors of the enzyme carbonic anhydrase for the treatment of glaucoma. One of Merck's development candidates in this area, Trusopt™ (dorzolamide), became the first marketed drug in pharmaceutical history to result from a structure-based drug design program. Dr. Murcko is highly regarded as an innovator and champion of disruptive technologies. He has served on the editorial boards of many scientific publications, including the Journal of Medicinal Chemistry and Drug Discovery Today, and served as the Chair of the 2013 Gordon Research Conference in Medicinal Chemistry. He is a co-inventor on more than 40 issued patents and has co-authored more than 85 scientific articles.
Prof. Pande is currently the Director of the Program in Biophysics, Director of the Folding@home Distribtued Computing project, and a Professor of Chemistry and (by courtesy) of Structural Biology and of Computer Science at Stanford University. His current research centers on the development and application of novel cloud computing simulation techniques to address problems in chemical biology. In particular, he has pioneered novel distributed computing methodology to break fundamental barriers in the simulation of kinetics and thermodynamics of proteins and nucleic acids. As director of the Folding@home project (http://folding.stanford.edu), Prof. Pande has, for the first time, directly simulated protein folding dynamics with quantitative comparisons with experiment, often considered a “holy grail” of computational biology. His current research also includes novel computational methods for drug design, especially in the areas of protein misfolding and related diseases such as Alzheimer’s Disease.
Prof. Pande received a BA in Physics from Princeton University in 1992. There, he was first introduced to biophysical questions, especially in his undergraduate thesis research with Prof. Philip Anderson, a Nobel Laureate in physics. Three years later, in 1995, he received his PhD in physics from MIT, studying as a NSF Fellow under Profs. Toyoichi Tanaka and Alexander Grosberg. At MIT, Prof. Pande’s research centered on statistical mechanical models of protein folding and design, suggesting novel ways to design protein sequences to have the desired stability and folding properties. As a Miller Fellow working with Prof. Daniel Rokhsar at UC Berkeley, Prof. Pande extended this methodology to examine atomistic protein models, laying the foundations for his later work at Stanford University.
Prof. Pande has won numerous awards, including the Michael and Kate Bárány Award for Young Investigators from Biophysical Society (2012), Thomas Kuhn Paradigm Shift Award, American Chemical Society (2010), Fellow of the American Physical Society (2008), Irving Sigal Young Investigator Award from the Protein Society (2006), the MIT Indus Global Technovator’s Award (2004), a Henry and Camile Dreyfus Teacher-Scholar award (2003), being named to MIT’s TR100 (2002), and named a Frederick E. Terman Fellow (2002).